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Successful differential diagnosis of primary versus metastatic 
pulmonary adenocarcinomas by using gene mutation analyses: 
report of a case
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The differential diagnoses for primary or metastatic pulmonary 
malignant lesions are often difﬁcult. We used the patterns of some 
genetic alterations as a discrimination marker of multiple lung lesions. 
A 61-year-old Japanese woman underwent total thyroidectomy for 
the left thyroid cancer in 2004. The next year, she underwent a partial 
mastectomy for the right breast cancer without pathological nodal inva-
sions. As postoperative treatment, she had radiotherapy with 50Gy for 
local controls, and was treated with sequential chemotherapy by orally 
uracil and tegaful. After eight months, chest computed tomography 
(CT) by follow-up revealed two small nodules in the left lower lobe 
(the segments of S9 and S10, 10mm and 8mm, respectively). We clini-
cally diagnosed those lesions as metastatic lung cancer from treated the 
malignant lesions. She underwent partial pulmonary resections by us-
ing video assisted thoracoscopic approach for the malignant lesions on 
December 4, 2006. A nodule in the segment of S10 was pathologically 
diagnosed as primary lung cancer, but another nodule in the segment 
of S9 was pathologically diagnosed as poorly differentiated adeno-
carcinoma. Especially the S9 nodule morphologically was not able to 
judge by microscopic examination, whether primary lung cancer or 
metastatic lesions from the treated breast cancer. DNAs were extracted 
from parafﬁn-embedded tissue from each of the tumor. Direct sequenc-
ing analysis of p53 gene from exons 5-8 using genomic DNA and K-ras 
from codon 12 were performed for the differential diagnoses. A differ-
ent pattern of the distribution of p53 mutation in the two nodules was 
observed, and a same pattern of the distribution of p53 mutation was 
observed in the DNA samples of the S9 nodule and the treated breast 
cancer. The mutation was C to T pointmutation in codon 213 on the 
two lesions. However, K-ras mutation was not detected in each of the 
tumor sample. So, we diagnosed the S9 nodule as metastatic pulmonary 
carcinoma from the treated breast cancer on the result of p53 mutation 
analyses. When we especially need to differentiate between primary 
and metastasis for the diagnoses of multiple lung lesions, it is useful 
that the patterns of some genetic alterations are analyzed.
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Immunohistochemical expression of Cap43 protein in pathological 
stage IA nonsmall cell lungcancer
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Purpose: Cap43 is a 43Kda molecular weight protein induced in calci-
um, whose expression is induced in hypoxia, metallic ion, retinoid, p53 
and phorbol ester. Cap43 protein is expressed in a variety of organs, 
and in particular expression of Cap43 protein is high in prostate, ovary, 
colon and kidney. It is also reported that overexpression of Cap43 sup-
presses of metastasis and tumor growth of some malignancies, but its 
precise role remains unclear and there is not the report that elucidate 
the expression of Cap43 protein in lung cancer. In this study, expres-
sion of Cap43 protein in pathological stageIA non-small cell lung 
cancer (NSCLC) was evaluated using immunohistochemical staining 
and the relationship between Cap43 expression and clinicopathologic 
ﬁndings was examined.
Materials and Methods: Surgical resected specimens from 74 patients 
with pathological stageIA NSCLC were studied. All patients underwent 
surgical resection between January 1 1995 and December 312001in 
Department of Surgery at the Kurume University Hospital, Japan. 
Among these patients, 64 underwent lobectomy and 9 underwent wedge 
resection. NSCLC tissues (adenocarcinoma, 57; squamaous cell carci-
noma, 16; Unknown, 1) were obtained from 39 men and 35 women with 
a mean age of 66years (age range 45-84 years). Each tissue underwent 
immunohistochemical analysis using antibodies to Cap43. Expression of 
Cap43 protein was evaluated with cytoplasm and nucleus. Differences in 
survival rates and relapse-free survival were evaluated by log rank test. 
Results: Expression of Cap43 protein was not found in pulmonary nor-
mal tissue and found in only carcinoma tissue. Incidence rate in nucleus 
was 59.5% (44/74). Overexpression rate with cytoplasm was 71.6% 
(53/74). In recurrence cases, incidence rate in nucleus was 80% (16/20) 
and the overexpression rate with cytoplasm was 81% (17/20). On the 
other hand, in non-recurrence cases, incidence rate in nucleus was 52% 
(28/54) and the overexpression rate with cytoplasm was 68% (36/54). As 
for the ﬁve-year survival rate, the group of the expression of Cap43 pro-
tein in nucleus was 77.3% and the group of the no-expression of Cap43 
protein in nucleus was 85.7%. There was no statistical signiﬁcance dif-
ference (p=0.59). The group of the over expression of Cap43 protein with 
cytoplasm was 77.4% and the group of the non-overexpression of Cap43 
protein with cytoplasm was 85.7%. There was no statistical signiﬁcance 
difference (p=0.47). As for the relapse free survival, the group of the 
expression of Cap43 protein in nucleus was 68.2% and the group of the 
no-expression of Cap43 protein in nucleus was 80.0%. There was no 
statistical signiﬁcance difference (p=0.32). The group of the over expres-
sion of Cap43 protein with cytoplasm was 69.8% and the group of the 
non-overexpression of Cap43 protein with cytoplasm was 81.0%. There 
was no statistical signiﬁcance difference (p=0.37).
Summary: Our results suggest that Cap43 protein to be a likely tumor 
marker for NSCLC. 
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P53 codon 72 polymorphism and human papillomavirus infection 
in non-small cell lung cancer: associated with viral oncogene e6 
expression
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A polymorphism at codon 72 of the p53 tumor suppressor gene is as 
a possible determinant for cancer risk and particularly carcinomas 
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associated with HPV infection. Our recent report has shown that high-
risk HPV 16/18 infections were associated with female lung cancer 
incidences in Taiwan. To address the correlation between the different 
p53 genotypes, HPV infection and HPV oncoprotein expression in p53 
protein degradation of lung cancer, 60 health subjects and 141 primary 
lung cancer patients were included in this study. PCR-RFLP, nested-
PCR and immunohistochemial analysis were used to detect the p53 
codon 72 polymorphism, HPV 16/18 infection, HPV 16/18 E6 and p53 
protein expression. Immunohistochemistry data showed that HPV 16 or 
18 E6 protein was more frequently detected in female, adenocarcinoma, 
and nonsmoking lung tumors, compared with that of male, squamous 
cell carcinoma, and smoking lung tumors. Interestingly, HPV 16/18 E6 
expressions but not HPV 16/18 DNA were reversely correlated with 
p53 expression, which was further conﬁrmed by tissue in situ immu-
nostaining. Additionally, the frequency of p53 protein degradation in 
HPV 16/18 E6-positive/Arg homozygosity lung cancer tumors is much 
higher than that in the other three categorizes. This correlation was not 
found in HPV DNA infection. In conclusion, HPV 16/18 E6 proteins 
involvement in p53 inactivation to contribute to HPV-infected lung 
tumorigenesis is correlate with p53 genotypes.
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High Resolution Melting (HRM) analysis is an emergent technique that 
has enormous potential for the detection of DNA sequence changes. 
New instruments combined with next generation DNA intercalating 
dyes allow the discrimination of single base changes in PCR-ampli-
ﬁed products. The technology shows great promise for the detection of 
somatic mutations in clinical samples.
Clinical tumour samples present particular difﬁculties as the actual pro-
portion of tumour cells is highly variable and in many cases sequencing 
is not sufﬁciently sensitive to pick up the mutations. We developed as-
says to detect somatic gene mutations in exons 18-21 of the EGFR gene 
using HRM analysis. We also used assays for exon 2 of the KRAS gene 
and exon 20 of the HER2 gene. We validated these assays in a panel 
of 300 previously sequenced lung cancer biopsies. Sensitivity testing 
showed that the HRM assay was able to detect as little as 5% mutant 
sequence in a background of wild type DNA. HRM was able to readily 
detect sequence variation that was barely visible by sequencing leading 
to a lower rate of false negative results. These results demonstrate the 
utility of HRM analysis for the detection of somatic mutations in clini-
cal samples and for pre-screening of samples prior to sequencing. 
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Activated coagulation factors in human malignant effusions from 
patients with lung carcinoma
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We have shown that the thrombin Protease Activated Receptors PAR-1 
are expressed in primary cancer cells isolated from peritoneal and pleu-
ral malignant effusions (Oncogene 2005, 24: 8240-51). Here, our main 
goal was to evaluate several coagulation and thrombin activation ef-
fectors and markers in a series of 15 malignant effusions from patients 
with lung carcinomas (NSCLC, 11; SCLC, 4). All patients present a 
highly activated coagulation system in blood and their malignant effu-
sions, as indicated by high levels of prothrombin F1.2 fragments and 
D-dimers. Notably, we detected in the effusions all the coagulation fac-
tors of the tissue factor pathway inducing thrombin activation, namely 
factors FVII, FV, FX and FII, as well as high VEGF levels and IGF-II 
in mature and precursor forms. Fibrin clot formation also correlated 
with higher levels of free ionized calcium (iCa), suggesting that iCa 
and its binding protein albumin are regulatory factors for ﬁbrinogen-
esis in effusions. Consequently, thrombin, VEGF and IGF-II appear to 
converge in the promotion of survival and invasivity of the metastatic 
cancer cells from blood to the malignant effusions. Thus, we add new 
insights on the interconnections between blood coagulation disorders 
in cancer patients and thrombin activation in malignant effusions, 
including their functional interaction with PAR in metastatic cancer 
cells. Based upon these data we propose to counteract the metastatic 
cascades by targeted interaction with the coagulation system. Pos-
sible therapeutic approaches would be by the application of thrombin 
inhibitors, VEGF-directed antibodies, drugs targeting the VEGF and 
thrombin PAR signaling pathways such as thyrosin kinase or G-protein 
inhibitors. 
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Chromosomal Changes In Lung Cancer
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Lung Cancer is a major chest problem in our society. It may present 
as a mass, pleural effusion, superior vena caval syndrome or a MUO 
(Metastasis of unknown origin). This study was carried out to analyze 
chromosomal patterns in lung cancer and assess its role as a diagnostic 
aid in certain clinical situations. 
25 patients entered the study. All underwent a detailed work up for 
the primary and metastatic lesions. Tissue samples were obtained by 
transthoracic ultrasound guided ﬁne needle aspiration (FNA)/ 18 of 
these were from the primary site the lung, 5 from metastatic nodes and 
1 from a pleural aspirate, 1 from pulmonary metastasis. The samples 
were processed directly in overnight / 24 hours cultures. Cell division 
was arrested at metaphase with colchicine (Boehringer 50ml of 100 ug 
/ ml) and analyzed after GTG banding (ISCN 1991). 
Metaphases were recovered in 14/25 patients. Cell poor aspirates were 
the reason for culture failures in the remainder. Of the 14 successful 
cultures, 9 were from the lung 8 NSCLC and 1 SCLC) and 3 from 
metastatic nodes (one small cell carcinoma and one poorly differentia-
